中關村(000931.SZ):北京華素鹽酸阿羅洛爾片上市許可申請獲得受理
格隆匯7月2日丨中關村(000931.SZ)公佈,公司下屬公司北京華素製藥股份有限公司(簡稱:北京華素)於近日收到國家藥品監督管理局簽發的《受理通知書》,鹽酸阿羅洛爾片(規格:10mg)上市許可申請獲得受理。
鹽酸阿羅洛爾片是一種α-β受體阻滯劑,適用於治療原發性高血壓(輕度中度)、心絞痛、心動過速性心律失常、原發性震顫。本品進口原研藥已於1995年在中國境內獲批上市;目前境內已有3家仿製藥獲批上市;除北京華素外,已有4家境內企業提交了上市許可申請,現正在審評中;北京華素是第8家提交本品仿製藥上市許可申請的境內企業。截至本公告披露日,鹽酸阿羅洛爾片項目已累計投入研發費用609萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.